Semaglutide Patent Expiry in India: Price & Generic Impact | MetaGO

What the March 2026 Patent Expiry Changed for Indian Users

Table of Contents

Quick Answer
Novo Nordisk’s core Indian patent on semaglutide expired on 20 March 2026. By the next morning, about a dozen Indian drugmakers were selling generic versions, and from 1 April Novo cut its own starting-dose prices by 36% to 48%. The medicine became far cheaper. It did not become over-the-counter: every version still needs a doctor’s prescription.

What Happened in March 2026

On 20 March 2026, the patent that gave Novo Nordisk sole rights to semaglutide in India ran out. Semaglutide is the molecule inside the Ozempic and Wegovy injections and the Rybelsus tablet.

Nobody was caught off guard. The courts had cleared the ground months earlier: in December 2025 the Delhi High Court refused Novo an injunction against Dr Reddy’s, and on 9 March 2026 a division bench dismissed Novo’s appeal.

So the date arrived with nothing left to argue. Companies filed launch notices with the stock exchanges that weekend and briefed their sales teams within a day of expiry.

India got there years ahead of the West, where semaglutide stays protected into the early 2030s.

Two quieter moves shaped what followed. Novo had already cut Wegovy’s price by up to 37% in November 2025, and brought in partners to sell second brands of both medicines. The regulator moved too: on 10 March, ten days before expiry, the Central Drugs Standard Control Organisation (CDSCO) warned every manufacturer against direct or disguised promotion of these medicines to the public.

Generic Brands That Launched 

Twelve companies have a launch someone can point to, selling 20 brands between them, according to a six-month ledger of company statements, stock-exchange filings and dated pharmacy listings published in October 2026.

Other counts run higher. The market tracker Pharmarack counted 26 brands from 13 companies in March alone, and estimates of 40 companies circulated by September. The gap is mostly firms that hold an approval or a registered brand name but have not put a product on a shelf.

CompanyBrand namesFormatLaunched
Dr Reddy’sObedaDisposable pen; tablets from 20 May21 March
Sun PharmaSematrinity (diabetes), Noveltreat (weight management)Pens21 March
Zydus LifesciencesSemaglyn, Mashema, AltermeReusable multi-dose pen21 March
LupinSemanext, LivariseInjection, made by ZydusMarch
TorrentSembolic, SemalixPens and tablets21 March
AlkemSemasize, Obesema, HepaglidePens; prefilled syringe from 2 June21 March
GlenmarkGLIPIQVial and prefilled pen21 March
NatcoSemanat, SemafullMulti-dose vials21 March
Eris LifesciencesSundaeVials, made by Natco20 to 21 March
USVUsemaPens, with Dr Reddy’s21 March
MSN LaboratoriesSemabestPrefilled pen15 April
Corona RemediesWyntidePrefilled multi-dose penBy April

Read the format column closely and the market’s real shape appears. Zydus makes what Lupin sells, Natco makes what Eris sells, and Dr Reddy’s supplied Torrent and partnered with USV. Twenty brands come out of far fewer factories.

Approvals differ as well. Zydus and Alkem announced approval for both type 2 diabetes and chronic weight management, while Glenmark’s approval covers diabetes. Sun Pharma is the only launcher that sells the two uses under separate brand names.

How Far Prices Fell 

Prices fell hard, and the size of the fall depends on what you compare. The cheapest generic costs roughly one-seventh of what the original brand charged for its starting dose at launch, and the original brand itself costs a third to a half less at that dose.

The table shows each change as a percentage rather than a rupee price. List prices move with strength, pack size and pharmacy, while a percentage shows the scale of the change without ageing the page.

What is being comparedWhat changedChange
Ozempic starting dose (0.25 mg)Novo price cut, effective 1 April 2026About 36% lower
Wegovy starting dose (0.25 mg)Novo price cut, effective 1 April 2026About 48% lower
Ozempic and Wegovy, all strengthsAverage cut across dosesAbout 24% and 27% lower
Wegovy starting dose vs its June 2025 launchTwo cuts: November 2025 and April 2026About two-thirds lower
Poviztra (Emcure’s licensed Wegovy brand), starting strengthPrice cut from 3 April 2026About 55% lower
Cheapest generic vial vs Ozempic’s starting dose at launchMulti-dose vials from Natco and ErisAbout 85% lower
Diabetes-priced generic pens vs Ozempic’s starting dose at launchCompany-stated monthly prices, Alkem to Dr Reddy’sAbout 52% to 80% lower
Rybelsus tabletsNo price cut announcedNo change
Mounjaro (tirzepatide)Still under patent; no genericNo generic entry

Two patterns explain the spread. The device decides the price more than the molecule does: vials, where the user or clinic supplies the syringe, undercut every pen, and the two companies selling both formats priced the pen at more than three times the vial.

Strength matters too. Weight-management doses run higher than diabetes doses, so the weight-management side of the same molecule usually costs more.

Even after Novo’s cuts, its cheapest pen costs more than four times the cheapest generic vial.

Buyers moved quickly. By April, generics made up half of India’s semaglutide sales by value and about four in every five injectable units sold, according to Pharmarack. They won the units because they cost so much less.

What It Means for Ozempic and Wegovy Prices

Novo chose to cut before the generics could set the floor. On 31 March it announced reductions effective 1 April, taking the 0.25 mg starting dose of Ozempic and Wegovy to the same weekly price: a 36% cut for Ozempic and 48% for Wegovy.

The higher strengths fell less, about 24% for Ozempic and 27% for Wegovy on average. That detail matters more than the headline, because the starting dose is typically used only in the first month before the dose steps up.

Novo also fought with second brands. Emcure sells a licensed version of Wegovy as Poviztra, which cut its starting strength by about 55% from 3 April, and Abbott sells a licensed version of Ozempic as Extensior.

For someone already on Ozempic or Wegovy, price is no longer the only reason to consider a change, and not always a good one. A generic carries the same molecule in a different pen, with a different dose ladder and sometimes a different range of strengths. Any switch belongs in a conversation with the prescribing doctor.

Does It Affect Rybelsus?

Yes, though more slowly than the injections. Rybelsus is semaglutide in tablet form, approved in India for type 2 diabetes, and generic tablets arrived alongside the pens.

Torrent launched its Semalix tablets on 21 March, describing them as India’s first generic oral semaglutide. Dr Reddy’s followed on 20 May with Obeda tablets in 3, 7 and 14 mg, approved by CDSCO after a comparative clinical study in 288 people with type 2 diabetes in India.

The tablet is a harder thing to copy than the injection. A protein-based medicine swallowed as a pill should be broken down long before it reaches the blood.

A 2018 study in Science Translational Medicine showed how the original tablet gets past this. It carries an absorption helper (SNAC) that briefly shields the drug and lets it cross the stomach lining in a small patch right beside the dissolving tablet. Most tablets are absorbed further down, in the intestine.

That chemistry has an everyday consequence. The label asks for the tablet to be taken on an empty stomach with no more than half a glass of plain water, at least 30 minutes before the first food or morning chai.

Novo announced no price cut on Rybelsus. By June, generic tablets accounted for about half of the oral units sold but under a third of oral sales value, so the original brand has kept most of the tablet market’s money so far.

Does It Affect Mounjaro (Tirzepatide)?

Not directly. Tirzepatide is a different molecule, and its patents did not expire. The Indian Patent Office granted Eli Lilly tirzepatide patents in March 2025, with protection widely reported to run into the mid-2030s, and no generic tirzepatide has CDSCO approval.

Cipla’s Yurpeak can look generic. It is not: Lilly makes it and Cipla distributes it, as a second brand of the same original product.

The expiry still reached Monjaro sideways. In March, semaglutide’s share of India’s GLP-1 medicine market rose from 25% to 33% while tirzepatide’s slipped from 71% to 64%, according to Pharmarack data reported by Bloomberg.

People weigh the two because both have strong trial records. In the STEP 1 trial of semaglutide and the SURMOUNT-1 trial of tirzepatide, some participants lost up to 20% of their body weight. Results varied widely from person to person, and both trials paired the medicine with diet and activity support.

Neither molecule is a better choice in general. The right one depends on a person’s health, other conditions and how they tolerate the medicine, which is a decision for a qualified doctor.

Quality and Regulation: CDSCO’s Role

Patent expiry removed the legal block; it did not remove the safety check. Every generic needs marketing approval from CDSCO, which is headed by the Drugs Controller General of India (DCGI).

Some approvals landed before the patent fell. Natco received CDSCO approval in February 2026, and Dr Reddy’s says it was the first Indian company to receive DCGI approval for generic semaglutide.

The regulator has drawn the prescribing line tightly. Its 10 March advisory says these medicines must be prescribed by registered medical practitioners within their approved uses, and treats awareness campaigns that build brand recall as disguised advertising. The regulator has also stated that approval conditions limit prescribing to endocrinologists and internal medicine specialists, and for some uses cardiologists.

Enforcement followed within days. By 24 March, CDSCO had inspected 49 businesses and issued notices, and a 27 March advisory told state drug controllers to tighten checks on the whole supply chain.

The first real test came in July, and it was about quality rather than price. On 9 July Dr Reddy’s paused supply after some batches failed specification because of a problem with the active ingredient, and Torrent recalled select Semalix pen batches that Dr Reddy’s had made. Dr Reddy’s expects to resume supply by November.

One factory problem reached several brands at once. That is the hidden side of twenty brands from a handful of plants.

A user can protect themselves in three plain ways: buy only against a prescription, buy only from a licensed pharmacy, and keep the batch number printed on the pack.

What This Means If You’re Starting Now

For many families, cost has stopped being the first barrier. That shifts the real question from whether you can afford it to whether it is right for you, and the answer starts with Indian numbers.

India’s 2025 revised definition of obesity treats a BMI above 23 as generalised obesity and grades 25 and above as more advanced. It adds a waist test, 90 cm or more for men and 80 cm or more for women, and separates Stage 1 from Stage 2 by asking whether the weight is already affecting blood sugar, blood pressure, joints or daily life.

The need is large. The national ICMR-INDIAB-17 survey of more than 1.1 lakh adults found generalised obesity in 28.6% and abdominal obesity in 39.5%, which works out to about 25 crore adults with generalised obesity.

Here is the wrinkle most coverage misses. The prescribing labels still lean on older global cut-offs: tirzepatide’s Indian label, for example, lists a BMI of 30, or 27 with a weight-related condition. An Indian adult can meet the Indian definition of obesity and still sit below the label line, and weighing that gap is a doctor’s call, not a pharmacy counter’s.

Starting also means a plan that sits beside the medicine. CDSCO’s own advisory warns against anything that plays down diet, activity and behaviour, and the trials behind these medicines built both in. In most Indian homes that begins with the evening thali: an extra katori of dal or sprouts, one roti fewer, and a 20-minute walk after dinner.

A sensible order looks like this. Measure your BMI and waist at home first. Then book a consultation with a qualified doctor, carrying any recent blood sugar, blood pressure and cholesterol reports. Let the doctor decide on brand or generic, injection or tablet, and the dose ladder. Buy only against that prescription, from a licensed pharmacy.

Generic does not mean lesser, and cheaper does not mean casual. The supervision is what makes the lower price worth having.

Conclusion
Semaglutide’s core Indian patent expired on 20 March 2026, and twelve companies with a verifiable launch began selling 20 generic brands from the next day. The cheapest generic sits about 85% below the original brand’s launch price for its starting dose, and Novo cut its own starting doses by 36% to 48%. Rybelsus has generic tablet rivals; Mounjaro (tirzepatide) is still under patent, with no generic in India. Every version remains prescription-only, and CDSCO is actively policing promotion, supply and quality. Cheaper access makes a doctor’s assessment, using Indian BMI and waist cut-offs, more important rather than less.

Frequently Asked Questions

1. When did the semaglutide patent expire in India?

Novo Nordisk’s core Indian patent on semaglutide expired on 20 March 2026. Generic launches began on 21 March, after the Delhi High Court had refused Novo an injunction in December 2025 and dismissed its appeal on 9 March 2026. In the United States and Europe, the molecule stays protected into the early 2030s.

2. How many Indian companies launched generics?

Twelve companies had a verifiable public launch by early October 2026, selling 20 brands between them, including Dr Reddy’s, Sun Pharma, Zydus, Torrent, Alkem, Glenmark and Natco. Pharmarack counted 26 brands from 13 companies in March. Higher estimates include firms that hold approvals or registered brand names without selling a product.

3. How far did prices actually fall?

The cheapest generic vial costs about 85% less than Ozempic’s starting dose did at its December 2025 launch, and diabetes-priced generic pens cost about 52% to 80% less. From 1 April 2026, Novo cut its starting doses by 36% for Ozempic and 48% for Wegovy, with average cuts across strengths of about 24% and 27%.

4. Does the expiry affect Rybelsus too?

Yes. Torrent launched generic semaglutide tablets under the brand Semalix on 21 March 2026, and Dr Reddy’s launched Obeda tablets on 20 May after a comparative study in 288 people with type 2 diabetes in India. Oral semaglutide is approved in India for type 2 diabetes. Novo announced no price cut on Rybelsus.

5. What does this mean for users starting now?

Treatment costs far less, but every version still needs a prescription. A qualified doctor should assess you using Indian cut-offs (a BMI above 23, and a waist of 90 cm for men or 80 cm for women), then choose brand or generic, injection or tablet, and the dose. Buy only from a licensed pharmacy.

Medical Disclaimer
This article is for general education and is not medical advice. It does not recommend, promote or endorse any medicine or brand. Semaglutide and tirzepatide are prescription-only medicines in India and should be used only under the supervision of a qualified doctor who has assessed your health. Market details and prices change; figures here reflect publicly reported information as of October 2026. Speak to your doctor before starting, stopping or switching any medicine.
  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
  3. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
  4. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-489. doi:10.1016/S2213-8587(23)00119-5
  5. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S. Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr. 2025;19(1):102989. doi:10.1016/j.dsx.2024.102989
Picture of Dr. Kaushal Patel

Dr. Kaushal Patel

MBBS, MD (Medicine), [Cardiologist Specialist in Diabetology & Obesity Management]